Hypobetalipoproteinemia with Accumulation of an Apoprotein B-like Protein in Intestinal Cells

Immunoenzymatic and Biochemical Characterization of Seven Cases of Anderson's Disease

Marie-Elisabeth Bouma, Isabel Beucler, Lawrence-Paul Aggerbeck, Recaredo Infante, and Jacques Schmitz

Institut National de la Santé et de la Recherche Medicale, U9, Hôpital Saint-Antoine, 75012; *Centre National de la Recherche Scientifique UA 524; †Centre de Genetique Moleculaire, Centre National de la Recherche Scientifique; and ‡Service de Gastroenterologie Pediatrique, Departement de Pediatrie, Hôpital des Enfants Malades, 75015 Paris, France

Abstract

We describe here seven cases (from five kindreds) of Anderson's disease, which is characterized by diarrhea, steatorrhea, hypobetalipoproteinemia with low levels of cholesterol, triglycerides, and phospholipids, and failure to secrete chylomicrons after a fat meal. Enterocyte isolated from intestinal biopsies of patients after overnight fast showed numerous fat droplets, a histological picture resembling that of abetalipoproteinemia. Immunoenzymatic staining of the enterocytes demonstrated large amounts of material that reacted with a polyclonal antiserum to apolipoprotein B. Further, the immunoreactive material was found to react with several different monoclonal antibodies capable of recognizing both the B100 and B48 forms of apoprotein B, but not with any of several monoclonal antibodies capable of recognizing only B100. This suggests that the material in the enterocyte is the B48 form of apoprotein B or a fragment thereof. Additional findings included decreased low density lipoprotein levels with an abnormal chemical composition, abnormal high density lipoprotein, (HDL2) and HDL3 particle size distributions, and an abnormal HDL apoprotein composition. Increased amounts of proteins having electrophoretic mobilities similar to apo E and the E-AII complex were present. Finally, some cases exhibited additional protein components of apparent molecular weights between 17,000 and 28,000, which was similar to some cases of abetalipoproteinemia. These findings demonstrate that Anderson's disease is not due to the absence of synthesis of intestinal apo B and suggest that it is more complex than previously thought, affecting all the lipoprotein classes.

Introduction

In 1961, Anderson et al. (1) described the case of a 7-mo-old girl who exhibited a defect in fat transport in the intestinal mucosa. The clinical features included persistent diarrhea with steatorrhea and failure to thrive. Macroscopic observation of the mucosal surface of a jejunal biopsy showed a “white stipplinglike hoar frosting.” By light microscopy, villi were present in normal number and length but the intestinal cells were filled with lipid droplets. Plasma levels of carotenoids, vitamins A and E were decreased. Plasma levels of total lipids, cholesterol, phospholipids, and triglycerides were very low, and serum alpha and betalipoprotein levels were 50% of normal. No chylomicrons were noted in the circulation after a fat meal. Although the clinical picture and intestinal biopsy findings closely resembled those of a patient described by Salt et al. (2) with abetalipoproteinemia, Anderson's patient did not have acanthocytosis, retinitis pigmentosa, or neurological abnormalities, and did have betalipoproteins in her plasma, although in reduced amounts. Anderson suggested that the primary defect in this syndrome was related to the synthesis of chylomicrons within the intestinal cells.

Subsequently, several other cases were described (3–8). The disease is characterized by diarrhea with steatorrhea, typical macroscopic and histological findings in the intestinal biopsy after an overnight fast, and decreased amounts of cholesterol in the plasma. The digestive symptoms are alleviated with resumption of normal growth by institution of a low-fat diet supplemented with liposoluble vitamins and essential fatty acids. The frequency of this disease among siblings and consanguineous relationships in the family of affected individuals suggests an autosomal recessive mode of inheritance.

The etiology of the disease is as yet unknown. In abetalipoproteinemia and homozygous hypobetalipoproteinemia, involving hepatic and intestinal apoprotein B (apo B100) genetic defects, fat malabsorption is always present and chylomicrons are absent from postprandial serum, suggesting that apo B synthesis is necessary for production and export of chylomicrons. A new mutant of abetalipoproteinemia (normotriglyceridemic abetalipoproteinemia) has been recently reported (9, 10). In these patients, only the hepatic form of apo B is synthesized and, thus, intestinal fat absorption and chylomicron production is normal, including the appearance of the intestinal form of apo B (B48) in the plasma after a fatty meal. Since these interesting observations suggest a separate genetic control of the intestinal and hepatic forms of apo B, the existence of an isolated defect of apo B production by the intestine which must result in fat malabsorption and lack of chylomicron secretion may be predicted.

1. Abbreviations used in this paper: apo, apoprotein; B48, intestinal form of apo B; B100, hepatic form of apo B; VHDL, very high density lipoprotein.
The aim of this study in a new series of seven patients from five kindreds with Anderson’s disease is to gain further information on the primary defect responsible for the impaired fat transport in the intestinal mucosa. This defect could result from a deletion of apo B or from translational or posttranslational abnormalities in the protein structure, or from a block in the cellular transport of chylomicrons. Recently, some patients with hypobetalipoproteinemia and a coeliaclike syndrome have been reported (11, 12) who resemble the Anderson’s disease patients described in this paper. Our immunocytochemical studies using polyclonal and monoclonal antibodies to low density lipoprotein (LDL) clearly show that although there are no circulating chylomicrons even after a fat meal, there are large amounts of immunoreactive apo B-like material present in the patients’ enterocytes, and that this material resembles the B48 as opposed to the B100 form of apo B. Further, the physical and chemical characterization of the circulating lipoproteins and their apoproteins reveal several additional abnormalities, some of which resemble those found in abetalipoproteinemia.

Methods

Description of the patients. M.K., born 9/26/68, was the 9th child in a sibship of 12; his Algerian parents were cousins. Diarrhea began at 4 mo; at 10 mo of age, coeliac disease was suspected and a gluten-free diet was started without any beneficial effect. When he was admitted to the hospital for the first time at 3 yr and 3 mo, he presented with growth retardation (89 cm, 10,800 kg), a distended abdomen, and loose stools. Hypocholesterolemia (total plasma cholesterol, 77 mg/dl) and an important steatorrhea (17.5 g/d) were present. An intestinal biopsy showed fat-loaded enterocytes in an otherwise normal mucosa. In the absence of acanthocytosis and neurological signs, the diagnosis of Anderson’s disease was made and M.K. was put on lipid-free diet. After a 1-yr period of strict adherence to the diet leading to the disappearance of the digestive symptoms and to catch-up growth, the diet was irregularly followed and symptoms recurred.

A.B., born 6/23/76, was the fourth of four children from Algerian parents. As cows’ milk was introduced into her diet at 17 d, she began to vomit, but her stool remained normal. At 4 mo of age, when first seen at the hospital, she was malnourished (63 cm, 4.430 kg) and had a grossly distended abdomen. Hirschsprung disease, cystic fibrosis, and cows’ milk protein intolerance were suspected and refuted. The latter diagnosis led to an intestinal biopsy that showed typical fat-loaded enterocytes. Hypocholesterolemia (116 mg/dl) and steatorrhea (5.6 g/d) were, thus, easily explained. A lipid-free diet was started. It has been strictly followed since then and A.B. is now a healthy young girl with a normal neurological examination.

S.Z., born 1/21/79, was the 11th child in a sibship of 12 from Algerian parents related at the sixth generation. The major symptom was intermittent diarrhea, which began at 2 mo of age, and was soon associated with failure to thrive. S.Z. was first admitted to the hospital at 13 mo of age with growth retardation (66.5 cm, 6,650 kg), malnutrition, and liquid or loose stools. Fat malabsorption was not major (3.9 g/d) but hypolipemia was clearcut: total plasma cholesterol was 66 mg/dl. The presence of fat-loaded enterocytes in the intestinal biopsy led to the diagnosis of Anderson’s disease and to the prescription of a lipid-free diet. Strict adherence to the diet resulted in a year of catch-up growth, and now S.Z. is growing normally.

K. and Y.Z., born 9/24/67 and 3/26/70, respectively, are two of S.Z.’s older brothers, the seventh and eighth children of the family. Both had frequent episodes of diarrhea and retarded growth during their childhood. When Anderson’s disease was diagnosed in S.Z., their father brought K. and Y.Z. to the hospital. They were first seen at 12 yr, and at 10 yr and 5 mo of age, respectively, with short statures (129 cm, 29 kg, and 120 cm, 24 kg, respectively) and loose stools. Both were hypo-
or mouse monoclonal antibody to paramaecium surface antigen (kindly provided by Drs. Y. Cappedeville and F. Caron, Centre de Génétique Moléculaire, Centre Nationale de La Recherche Scientifique, France) followed by peroxidase-labeled antiserum to rabbit or mouse immunoglobulin; and (d) Graham-Karnovsky reaction alone to determine endogenous peroxidase.

Two series of monoclonal antibody–producing hybridoma cell lines, L3, L5, L7, L9 (developed by the Clin Midy Research Center, Montpellier, France), and SC2, SC3, SC10, were obtained by fusion of NS1 and SP20 myeloma cells, respectively, with spleens from BALB/c mice immunized with human serum LDL (density 1.024–1.050 g/ml). The preparation and many of the characteristics of these antibodies have already been described (20, 21); rabbit polyclonal antibodies to LDL and to total apo C and apo CIII were prepared previously described (22). The specificity of the antibodies with respect to the various forms of apo B (according to the nomenclature of Kane et al. [23]) were determined by enzymimunooassay (Goldstein, S., unpublished results) and by immunoblotting of sodium dodecyl sulfate (SDS) polyacrylamide gels of chylomircons, very low density lipoprotein (VLDL), and LDL according to Salmon et al. (20) and are summarized in Table I. One group of antibodies was capable of recognizing both the B100 and B48 forms of apo B as illustrated in Fig. 1 by the rabbit polyclonal and the L9 and SC3 as SC10 (data not shown) monoclonal antibodies. The other group, illustrated by L7 and SC2 in the figure and L3, (L5 not presented), recognized the B100 but not the B48 form of apo B. For the studies described here the L3, L5, L7, and L9 antibodies were used in the form of purified immunoglobulins, while the SC2, SC3 and SC10 antibodies were used in the form of murine ascitic fluid.

Ultracentrifugal fractionation of serum lipoproteins. Blood samples were obtained from subjects fasting (12 h) or 3 h after a fat meal (50 g lipid). Serum was separated from the blood clot by centrifugation at 3,000 g, 4°C, for 15 min. The serum was then added with EDTA (1 mM) pH 8.6 and sodium azide (0.05%). Sequential separation of lipoproteins was begun immediately as described by Havel et al. (24) using a Beckman L3 50 ultracentrifuge at 10°C and a 50.3 titanium rotor to obtain the following fractions: VLDL, density < 1.006 g/ml (155,000 g for 14 h), LDL, density 1.006–1.063 g/ml (115,000 g for 16 h), high density lipoprotein, (HDL), density 1.063–1.085 g/ml (115,000 g for 18 h), HDL2 density 1.085–1.125 g/ml (180,000 g for 22 h), HDL3 density 1.125–1.21 g/ml (180,000 g for 24 h), and very high density lipoprotein (VHDL), density 1.21–1.25 g/ml (180,000 g for 24 h). Lipoprotein fractions were dialyzed against several changes of 2 mM sodium phosphate buffer, pH 7.5, containing 0.5 mM EDTA and 3 mM sodium azide. After dialysis, fractions were stored at 4°C and analyses were performed within 24 h of preparation.

Lipoprotein analysis. Total cholesterol (25), triglycerides (26), and phospholipids (27) were directly measured in serum using enzymatic techniques in an autoanalyzer (Corona, Clinicon-Boehringer, Meylan, France). Serum apo A1 (28) and apo B (29) were determined by electroimmunooassay using monospecific antisera (30). Lipoprotein fractions were delipidated as described by Brown et al. (31) and total cholesterol, triglycerides, and phospholipids were measured as described above. Free fatty acids and cholesterol ester fatty acyl groups were not measured. Protein was assayed according to Peterson (32).

**Table I. Specificities of the Monoclonal Antibodies toward the Various Forms of Apo B**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>B100</th>
<th>B74</th>
<th>B26</th>
<th>B48</th>
</tr>
</thead>
<tbody>
<tr>
<td>L3</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>±</td>
</tr>
<tr>
<td>L5</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>L7</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>L9</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>SC2</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SC3</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>SC10</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* According to the nomenclature of Kane et al. (21). For 14 h, LDL, density 1.006–1.063 g/ml (115,000 g for 16 h), high density lipoprotein, (HDL), density 1.063–1.085 g/ml (115,000 g for 18 h), HDL2 density 1.085–1.125 g/ml (180,000 g for 22 h), HDL3 density 1.125–1.21 g/ml (180,000 g for 24 h), and very high density lipoprotein (VHDL), density 1.21–1.25 g/ml (180,000 g for 24 h). Lipoprotein fractions were dialyzed against several changes of 2 mM sodium phosphate buffer, pH 7.5, containing 0.5 mM EDTA and 3 mM sodium azide. After dialysis, fractions were stored at 4°C and analyses were performed within 24 h of preparation.

**Figure 1. Western blots illustrating the specificities of representative antibodies (~20 μg IgG/ml) towards the various forms of apo B: B100, B74, B48, and B26. Lane 1, chylomicrons (60 μg protein); 2, VLDL (30 μg protein); 3, LDL (10 μg protein). Some antibodies, as illustrated by the rabbit polyclonal and the L9 and SC3 monoclonal antibodies, recognize both the B100 (o) and B48 (o) forms of apo B. Other antibodies, illustrated by L7 and SC2, recognize only the B100 form. The fainter band corresponding to B48 in chylomircons as compared with that obtained with VLDL is due to the smaller amount of apo B loaded on the gels.**
The morphology of the lipoproteins in isolated fractions was investigated by negative staining with 2% sodium phosphotungstate in 10 mM sodium phosphate buffer, pH 7, using a Phillips 301 electron microscope (33). The resolution of the microscope was determined using potassium chloroplatinate crystals and graphite and was found to be >0.4 nm. Low magnification calibration (to about ×10,000) was performed with a grating replica (34,864 lines/in.) and intermediate magnifications (to about ×50,000) with glutaraldehyde-fixed, negatively stained catalase crystals (34). Photographic enlargements were calibrated by comparing particle sizes on the negative with those on the paper.

Apolipoproteins analysis. Apolipoproteins were analyzed by isoelectric focusing in a pH 4–6.5 ampholine gradient (35) and by SDS polyacrylamide gel electrophoresis: 4% polyacrylamide gels for apo B-containing fractions and 15% polyacrylamide gels for apo A-containing fractions (36).

Isoelectric focusing gels were stained with Coomasie Blue G250. SDS polyacrylamide gels were stained with Coomasie Blue R-250 according to Fairbanks et al. (37) or with silver according to Oakley et al. (38). Approximately 20 μg protein was applied to the gels for analysis of apo B (Coomassie staining). In the case of HDL apoproteins, either 75 μg (for Coomassie staining) or 200–300 ng (for silver staining) were applied to the gels. Duplicate samples were prepared non-reduced and reduced by addition of an excess of β-mercaptoethanol.

Results

Histochemical and immunoenzymatic staining of isolated enterocytes

Oil red staining. In contrast to normal fasting children or adults in whom intestinal cells contain only small Oil red O-positive lipid droplets localized at the apical portion of the cell (Fig. 2 A), fasting Anderson’s disease patients have intestinal cells filled with numerous lipid droplets scattered at the apical and basal cell regions (Fig. 2 C and D). In two patients, M.B. and A.H., the Oil red O staining was heterogeneous with some cells being destined with fat droplets (Fig. 2 C), while others were long and without lipid droplets (Fig. 2 B) and resembled the enterocytes from normal fasting individuals.

Immunoenzymatic staining. Immunoenzymatic staining for apo B also showed marked differences among intestinal cells from normal individuals and from patients with Anderson’s disease, and with respect to the antibody used. Polyclonal antibodies to apo B (LDL) (Fig. 3 A) or monoclonal antibodies specific for both B100 and B48 (L9 [Fig. 4 A] and SC10 [Fig. 4 B]) gave weak reactions that were located at the supranuclear region of normal enterocytes (most intense with the polyclonal anti apo B). Using monoclonal antibodies reacting with B100 (L5, L7), but not with B48, the cell staining was minimal or absent (Fig. 4 C). In contrast, cells from Anderson’s disease patients showed strong brown cytoplasmic peroxidase staining surrounding the large lipid droplets (Fig. 4, B and C) when the polyclonal anti-apo B antiserum was used. Prior absorption of the polyclonal antiserum with apo B completely prevented the reaction (Fig. 3 D). Only biopsies from M.B. and A.H. could be examined as well with monoclonal antibodies. Intense immunoperoxidase staining of intestinal cells was obtained with three different monoclonal antibodies (L9, SC3, and SC10), recognizing both the B48 and B100 forms of apo B. The material reacting in fasting patients’ cells (Fig. 4, D–G) was clearly more abundant than in the fasting normal individuals (Fig. 4 A). Immunoperoxidase staining of apo B with L9, SC3, and SC10, in cells from M.B. and A.B., was more conspicuous in the larger fat-loaded cells (Fig. 4, D–G) than in enterocytes containing few or no lipid droplets in the cytoplasm, which are indistinguishable from normal cells (results not shown). In contrast, when three other monoclonal antibodies (L5, L7, and SC2) recognizing only apo B100 were used (Fig. 4 H), no immunoperoxidase reaction was obtained. In the case of L3, which strongly recognizes B100 but only weakly recognizes B48, patients’ cells stained weakly (Fig. 4 J). Strong immunoperoxidase staining of enterocytes from the patients was also noted using polyclonal antisera to apo C (total), apo CII, and apo CIII (results not shown). The significance of these findings was validated by the fact that normal human hepatocytes and Hep-G2 cells showed marked peroxidase staining with all the monoclonal and polyclonal antibodies (results not shown). Furthermore, the control reactions including those using a monoclonal antibody against paramecia surface antigen (Fig. 4 J) or the peroxidase label alone (Fig. 4 K) were negative.

Figure 2. Histochemical staining of fat droplets in isolated enterocytes. Oil red O staining shows small lipid droplets in the apical portion of enterocytes from normal fasted individuals (A) while enterocytes from patients with Anderson’s disease are heavily fat laden (C and D). Some enterocytes from patients are long and without lipid droplets (B). × 500.

Hypobetalipoproteinemia with Apoprotein B48 in Enterocytes
After an overnight fast, all patients displayed marked hypercholesterolemia and decreased phospholipid levels but had a triglycerideremia within the normal range (Table II). Agarose electrophoresis revealed decreased levels of beta and alpha lipoproteins; prebetalipoproteins were normal. Plasma levels of apolipoproteins A1 and B were only 20–70% of normal control values (Table II). Ultracentrifugal isolation of lipoproteins confirmed that the low density classes (density < 1.063 g/ml) were only 30–75% of the levels found in normal children of the same age; moreover, their composition was altered; triglycerides were markedly increased and total cholesterol was decreased, whereas protein and phospholipids were essentially normal (Table III). In two patients (A.B. and A.H.), enough plasma could be obtained to isolate VLDL and LDL. LDL had an abnormally high content in triglycerides and phospholipids relative to cholesterol (triglycerides, 18%, cholesterol, 25%, protein, 20%, and phospholipids, 37%). HDL were also markedly decreased, only 20–30% of normal values, but had a normal composition (Tables IV and V). The ratio of HDL₂ to HDL₃ was normal or slightly decreased except in A.B., in whom the total mass of HDL₂ and HDL₃ was the same. In two cases (M.K. and K.Z.), the HDL₃ level and composition were normal. 3 h after a 50-g sunflower oil test meal, all of the four subjects tested showed small increases in plasma triglycerides (Table II). On the average, phospholipids, total cholesterol, apo B, and apo Al also increased, although less markedly than the triglycerides (Table II). In spite of slight changes, the subjects remained markedly hypercholesterolemic with decreased levels of phospholipids, apo B, and apo Al, but with normal triglyceride levels. In spite of postprandial triglyceride increase, chylomicrons were not evident either by ultracentrifugation or by agarose electrophoresis, which showed only slight increase in the alpha and prebetalipoprotein bands.

**Plasma lipid and lipoprotein chemical composition:** response to fat loading

**Electron microscopy of the low and high density lipoproteins**

Low density lipoproteins from three patients (H.A., A.B., and M.B.), HDL₂ from four patients (H.A., A.B., M.B., and M.K.)
Figure 4. Immunoenzymatic localization in isolated enterocytes of apo B with monoclonal antibodies against LDL. Enterocytes from normal fasted individuals show light supranuclear immunoperoxidase staining when antibodies specific for both B100 and B48 were used, L9 (A) or SC10 (B). Only minimal staining is observed with an antibody specific for only B100, L5 (C). Intense cytoplasmic staining around lipid droplets is seen in enterocytes from patients when antibodies specific for both B100 and B48 are used: patient (M.B.), antibody L9 (D); patient (M.B.), antibody L9 (E); patient (M.B.), antibody SC10 (F); and patient (M.B.), antibody SC3 (G). In contrast, minimal or no staining of enterocytes from patients is seen when antibodies specific for only B100 are used: patient (M.B.), antibody L5 (H); and patient (M.B.), antibody L3 (I). Controls, enterocytes from patients with monoclonal antibody to paramecium surface antigen (J) or with peroxidase-labeled antisera alone (K), show no staining. Magnification × 500 except D, × 1,300.
Table II. Plasma Lipid and Apoprotein Levels Fasting and 3 h after an Oral Fat Load*  

<table>
<thead>
<tr>
<th>Subject</th>
<th>Apo B Fasting</th>
<th>Apo A Fasting</th>
<th>PL† Fasting</th>
<th>C‡ Fasting</th>
<th>TG‡ Fasting</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/dl 3 h</td>
<td>mg/dl 3 h</td>
<td>mg/dl 3 h</td>
<td>mg/dl 3 h</td>
<td>mg/dl 3 h</td>
</tr>
<tr>
<td>K.Z</td>
<td>21 20</td>
<td>26 26</td>
<td>38 40</td>
<td>40 40</td>
<td>43 44</td>
</tr>
<tr>
<td>Y.Z.</td>
<td>23 23</td>
<td>26 26</td>
<td>34 33</td>
<td>36 35</td>
<td>43 47</td>
</tr>
<tr>
<td>S.Z.</td>
<td>26</td>
<td>53</td>
<td>ND§</td>
<td>69</td>
<td>133</td>
</tr>
<tr>
<td>A.B.</td>
<td>44 48</td>
<td>69 77</td>
<td>67 70</td>
<td>69 72</td>
<td>59 68</td>
</tr>
<tr>
<td>A.H.</td>
<td>46</td>
<td>67</td>
<td>ND§</td>
<td>87</td>
<td>123</td>
</tr>
<tr>
<td>M.B.</td>
<td>25</td>
<td>66</td>
<td>ND§</td>
<td>70</td>
<td>67</td>
</tr>
<tr>
<td>M.K.</td>
<td>36 40</td>
<td>64 62</td>
<td>67 69</td>
<td>60 65</td>
<td>53 65</td>
</tr>
<tr>
<td>Normal fasting range</td>
<td>60–100</td>
<td>120–160</td>
<td>150–225</td>
<td>116–195</td>
<td>45–110</td>
</tr>
</tbody>
</table>

* 50-g fat load. † PL, total phospholipid; C, free plus esterified cholesterol; and TG, triglycerides. § ND, Not enough material for determination.

and HDL₃ from five patients (H.A., A.B., M.B., M.K., and K.Z.) were examined by electron microscopy after negative staining with 2% phosphotungstic acid. The patients' low density lipoproteins exhibited a spherical morphology resembling that typically observed upon negative staining of normal low density lipoproteins (Fig. 5, A–C). The average diameters of LDL from H.A., A.B., and M.B. were 23.8±3.9 (1,018 particles), 23.3±5.3 (573 particles), and 21.7±1.8 nm (665 particles), respectively, slightly smaller than for LDL obtained from normal individuals, which was 2.65±2.0 nm. Average particle diameters for the HDL₂ fractions from H.A., A.B., and M.K. were 7.5±1.0 (795 particles), 11.1±2.0 (502 particles), 7.1±1.3 (795 particles), and 12.4±2.9 nm (950 particles), respectively, as compared with 10.0±2.0 nm for HDL₃ from normal individuals. The particles, in all instances, were slightly irregular in shape. Irregularly shaped particles were also observed for all the HDL₃ subfractions (Fig. 5, H–L). The average particles diameters of HDL₃ from H.A., A.B., M.B., M.K., and K.Z. were 8.4±1.6 (540 particles), 8.8±1.5 (704 particles), 6.9±1.5 (608 particles), 14.4±3.9 (648 particles), and 8.5±1.6 nm (891 particles), respectively, as compared with 8.8±1.6 nm for normal HDL₃. Particles from all the HDL subfractions were found to exhibit hexagonal packing arrangements under certain conditions; however, no square lattices as described for abetalipoproteinemic LDL or HDL were observed, even at very high particle concentrations.

**Characterization of the low density apolipoprotein**

Analysis by electrophoresis on 4% polyacrylamide gels containing SDS showed that, after delipidation, the apoproteins from the lower density lipoprotein classes (density < 1.006 or density < 1.063 g/ml) of A.B. and H.A. exhibited a single high molecular weight protein with an electrophoretic mobility corresponding to that of B100 as found in normal human LDL (Fig. 6). No protein having an electrophoretic mobility corresponding to that of B48 was observed. Similar results were obtained with apoproteins from patients having received an oral fat load.

**Soluble apolipoproteins**

Electrophoresis in 15% polyacrylamide gels of the soluble apoproteins from lipoproteins of density < 1.006 g/ml or < 1.063 g/ml showed the presence of CII, CIII, and E apoproteins.

Isoelectric focusing showed that the isomorphs of apo CII (CIIa, CIIb, and CIIc) and of apo E (E₂, E₃, and E₄) were all present, primarily in the density < 1.006-g/ml fraction with only trace amounts in the density 1.006–1.063-g/ml fraction. In only

Table III. Content and Composition of Lipoproteins: Density < 1.063 g/cm³ Fasting and 3 h after an Oral Fat Load*  

<table>
<thead>
<tr>
<th>Subject</th>
<th>Total mass Fasting</th>
<th>PL† Fasting</th>
<th>PL‡ Fasting</th>
<th>C‡ Fasting</th>
<th>TG‡ Fasting</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/dl 3 h</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>K.Z</td>
<td>73 82</td>
<td>20 20</td>
<td>27 27</td>
<td>22 20</td>
<td>31 33</td>
</tr>
<tr>
<td>Y.Z.</td>
<td>70 92</td>
<td>23 19</td>
<td>20 16</td>
<td>23 22</td>
<td>34 42</td>
</tr>
<tr>
<td>A.B.</td>
<td>175 193</td>
<td>21 22</td>
<td>35 33</td>
<td>23 23</td>
<td>21 22</td>
</tr>
<tr>
<td>A.H.</td>
<td>250</td>
<td>19</td>
<td>22</td>
<td>19</td>
<td>40</td>
</tr>
<tr>
<td>M.B.</td>
<td>127</td>
<td>19</td>
<td>25</td>
<td>24</td>
<td>32</td>
</tr>
<tr>
<td>M.K.</td>
<td>107 137</td>
<td>21 20</td>
<td>19 19</td>
<td>24 21</td>
<td>36 40</td>
</tr>
</tbody>
</table>

* 50-g fat load. † PL, protein; PL, total phospholipids; C, free plus esterified cholesterol; and TG, triglycerides.
Table IV. Content and Composition of HDL₃* Fasting and 3 h after an Oral Load‡

<table>
<thead>
<tr>
<th>Subject</th>
<th>Total mass</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fasting 3 h</td>
<td>P§</td>
</tr>
<tr>
<td></td>
<td>mg/dl</td>
<td>%</td>
</tr>
<tr>
<td>K.Z.</td>
<td>17</td>
<td>50</td>
</tr>
<tr>
<td>Y.Z.</td>
<td>16</td>
<td>50</td>
</tr>
<tr>
<td>A.B.</td>
<td>63</td>
<td>44</td>
</tr>
<tr>
<td>A.H.</td>
<td>43</td>
<td>35</td>
</tr>
<tr>
<td>M.B.</td>
<td>18</td>
<td>50</td>
</tr>
<tr>
<td>M.K.</td>
<td>28</td>
<td>46</td>
</tr>
<tr>
<td>Normal fasting range</td>
<td>100-115</td>
<td>48-52</td>
</tr>
</tbody>
</table>

* Density 1.085–1.125 g/cm³.  ‡ 50-g fat load.  § P, protein; PL, phospholipids; C, free plus esterified cholesterol; and TG, triglycerides.

one case, M.K., were all four isomers of apo AI (Al₁, Al₂, Al₃, and Al₄) present with the amounts of Al₁ and Al₂ being larger than Al₃ and Al₄ (results not shown).

After 15% polyacrylamide electrophoresis, both HDL₂ and HDL₃ from two patients with Anderson’s disease (H.A. and A.B.) had apoprotein patterns close to that of normal HDL₂ [Fig. 7, A, B, E, and F] which contained, principally, apo AI, apo Al II, apo C7, and an unidentified protein band (labeled J in Fig. 7) with mobility slightly slower than apo Al II. In addition, the patients’ HDL contained higher amounts of apo E, E–AlI complex, and some nonidentified high molecular weight bands (apparent molecular weight > 46,000). In normal apo HDL, the major protein band with electrophoretic mobility intermediate between Al and AIII migrates closer to AI (labeled J in Fig. 7).

In contrast, the apo HDL₂ (not shown) and apo HDL₃ of M.K., Y.Z., and K.Z. (Fig. 7 C) were characterized by larger amounts of apo E–AlI complex, apo E, nonidentified high molecular weight material, and by the presence of an additional protein band of intermediary mobility between AI and AlII (labeled J in Fig. 7). Upon reduction with β-mercaptoethanol, the E–AlI complex dissociated, but the mobility of the protein bands situated between AI and AlII was not modified (Fig. 7 G); HDL₂ and HDL₃ obtained from patients after an oral fat load gave similar apoproteins electrophoretic patterns. The unusual apo HDL electrophoretic pattern of M.K., Y.Z., and K.Z. resembled that of apo HDL₂ and apo HDL₃ from two patients, S.L. and M.P. (not shown), with abetalipoproteinemia (Fig. 7 D and H), who also exhibited other protein bands with electrophoretic mobilities between those of AI and AlII as well as the increased amounts of apo E and E–AlI complex and high molecular weight bands. By isoelectric focusing, the apoproteins from the HDL subfractions (HDL₁, HDL₂, and HDL₃) of A.B., Y.Z., and K.Z. resembled normal HDL apoproteins having the major apo E isomers (E₂, E₃, E₄), the four major apo AI isomers (Al₁, Al₂, Al₃, and Al₄), plus a weak additional band in the acidic range, two bands for apo AlI (the most intense being the most basic one), the three CIII isomers (CIII₀, CIII₁, and CIII₂), and CII, although in decreased amounts relative to normal apo HDL (Fig. 8, A, B, and D).

One subject, M.K., had an apo HDL isoelectric focusing pattern that differed from those of normal individuals and the other Anderson’s disease patients. In addition to the protein bands previously described, the apo HDL (apo HDL₁, as well as apo HDL₂ and apo HDL₃) from this patient had three ad-

Table V. Content and Composition of HDL₃* Fasting and 3 h after an Oral Load‡

<table>
<thead>
<tr>
<th>Subject</th>
<th>Total mass</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fasting 3 h</td>
<td>P§</td>
</tr>
<tr>
<td></td>
<td>mg/dl</td>
<td>%</td>
</tr>
<tr>
<td>K.Z.</td>
<td>58</td>
<td>50</td>
</tr>
<tr>
<td>Y.Z.</td>
<td>35</td>
<td>54</td>
</tr>
<tr>
<td>A.B.</td>
<td>64</td>
<td>53</td>
</tr>
<tr>
<td>A.H.</td>
<td>63</td>
<td>57</td>
</tr>
<tr>
<td>M.B.</td>
<td>39</td>
<td>51</td>
</tr>
<tr>
<td>M.K.</td>
<td>58</td>
<td>51</td>
</tr>
<tr>
<td>Normal fasting range</td>
<td>200</td>
<td>51-53</td>
</tr>
</tbody>
</table>

* Density 1.125–1.21 g/cm³.  ‡ 50-g fat load.  § P, protein; PL, phospholipids; C, free plus esterified cholesterol; and TG, triglycerides.
Figure 5. Electron microscopy of isolated lipoproteins. Negative staining with 2% phosphotungstic acid of LDL from A.B. (A), H.A. (B), and M.B. (C); of HDL₂ from H.A. (D), M.B. (E), A.B. (F), and M.K. (G); and of HDL₃ from M.K. (H), M.B. (I), A.B. (J), H.A. (K), and K.Z. (L). The scale for A, B, and C is denoted by the bar in A which represents 100 nm. The scale for D-L is denoted by the bar in D, which also represents 100 nm.

Additional protein bands, two slightly more acidic than the apo E₂ and E₃ isomorphs, respectively, and one present between the strongest AII isomorph and the most acidic AI isomorph (Fig. 8, C and E). This pattern resembled that of apo HDL from a patient with abetalipoproteinemia (S.L.) (Fig. 8 F). Similar patterns were obtained after an oral fat load.
the jejunal mucosa suggest that absorption of fatty acids into the intestinal cells and subsequent esterification into triglycerides does indeed take place. However, a block in the normal exit of lipids from these cells is attested to by the absence of chylomicrons and intestinal VLDL after a fat load. Given the well-established role for apolipoproteins in intestinal fat absorption, one possible etiology for Anderson's disease could be the absence of B48. The results of the present study demonstrate that although B48 is apparently absent from the plasma, large amounts of material that react with a polyclonal antibody to apo B is nevertheless present in the enterocytes of patients with Anderson's disease. Compared with enterocytes from normal fasting individuals in which the immunoperoxidase staining is localized primarily in the supranuclear region corresponding to the Golgi apparatus, the reactive material of the enterocytes from fasting patients was markedly increased throughout the cytoplasm. This distribution resembles much more that seen in the cells of normal individuals after a fat meal and is consistent with an increased process of apoprotein synthesis and chylomicron formation (14, 39). Another very interesting observation is the heterogeneity observed among the enterocytes from patients with Anderson's disease. Some were long and without lipid droplets with little anti-apo B peroxidase staining, and resembled enterocytes from normal fasting individuals, while others (from the same individual) were large and fat loaded and heavily anti-apo B peroxidase stained. This is not due to contamination of villus cells by crypt cells or by immature cells originating from the lower two-thirds of the villus, since intact biopsy sections show oil Red staining of one side but not the other of the upper one-third of some villi.

The nature of the immunoreactive material in the enterocytes of two patients was further defined using several different monoclonal antibodies, some of which recognize only the B100 form of apo B while others recognize both the B100 and B48 forms. The former antibody strongly reacted with liver cells, whereas the later ones reacted with normal and Anderson's patients' enterocytes, normal hepatocytes and Hep G2 cells. However, the B100-specific monoclonal antibodies strongly react with normal hepatocytes or Hep G2 cells, but not with enterocytes. All these results suggest that the immunoreactive material stored in the patients enterocytes is related to B48. Therefore, the etiology of

Discussion

The seven patients with intestinal malabsorption described here all exhibit features typical of Anderson's disease: diarrhea, steatorrhea, decreased serum cholesterol and phospholipids, decreased serum α- and β-lipoproteins, absence of chylomicrons postprandially, and intestinal cells filled with lipid droplets. The presence of serum LDL and the absence of acanthocytosis, retinitis pigmentosa, and ataxia, distinguishes the disease from abetalipoproteinemia, and the presence of heavy fat-laden enterocytes distinguishes Anderson’s disease from hypobetalipoproteinemia. The numerous Oil red O–positive lipid droplets in

Figure 5. Polycrylamide (4%) gel electrophoresis in SDS of apo B (10 μg) of VLDL and total LDL from Anderson’s disease patients. LDL from a normal individual (A), VLDL from H.A. (B), and total LDL density < 1.063 g/cm³ from A.B., before (C), and 3 h after an oral fat load (D). The arrows denote the top of the gel and the position of the tracking dye at the bottom of the gel.

Figure 6. Polycrylamide gel electrophoresis in SDS of apo B (10 μg) of VLDL and total LDL from Anderson’s disease patients. LDL from a normal individual (A), VLDL from H.A. (B), and total LDL density < 1.063 g/cm³ from A.B., before (C), and 3 h after an oral fat load (D). The arrows denote the top of the gel and the position of the tracking dye at the bottom of the gel.

Some patients, represented by A.B., have apo HDL gel patterns that resemble normal apo HDL, except for increased amounts of apo E, E–AII, and high molecular weight components. Other patients, represented by K.Z., have apo HDL gel patterns that resemble more closely those of apo HDL from abetalipoproteinemic patients, having additional protein bands with electrophoretic mobilities intermediate between AI and AI.
the disease does not involve the deletion of B48 in the enterocyte. Although the structure of the stored protein has not yet been established, it can be suggested that some abnormality in the amino acid sequence or a posttranslational defect (glycosylation, phosphorylation, tertiary structure, etc.) prevents the protein from binding to lipids, or the chylomicron from being secreted. Other defects independent from normal chylomicron production might also interfere with the transport and exocytosis of lipoproteins, including dysfunction of the microtubular system.

Alternatively, lack of synthesis or maturation of other apoproteins (apo A1, AII, AIV) could be responsible for a defect in chylomicron secretion. Since the precise role of these apoproteins in intracellular lipoprotein processing is unknown, genetic disorders could help in understanding the miscellaneous processes of lipoprotein assembly and secretion. In this respect, it must be emphasized that apoproteins A1, AII, AIV, and C are present in reduced amounts in the patients' plasma; in addition, the immature pro apo A1 form seems to be present in HDL (see Fig. 8 C), a finding that is under more extensive investigation. In any case, the present results attest to the importance of evaluating apoprotein synthesis at the cellular level in genetic diseases characterized by the absence or abnormally low plasma levels of lipoproteins. This is further underlined by our recent finding of a presence of apo B immunoreactive material in the intestinal cells from a child with abetalipoproteinemia (unpublished results). Previously reported immunofluorescence studies of patients with abetalipoproteinemia by Glickman et al. (14) failed to find any apo B in intestinal biopsies. Thus, presumably, the same phenotype, abetalipoproteinemia, could be the expression of different molecular genetic disorders.

In addition to the immunohistochemical findings, several other abnormalities were noted in patients with Anderson's disease. Levels of HDL were decreased in all our subjects in accordance with previously reported observations (6-8). Low HDL levels are not uncommon in other disorders involving apo B: normotriglyceridemic abetalipoproteinemia (9, 10), recessive abetalipoproteinemia (40), homozygous hypobetalipoproteinemia (41), and the syndrome described by Steinberg et al. (42). As compared with normal HDL2 and HDL3, we found increased amounts of apo E, and similarly with cases of abetalipoproteinemia, found increased amounts of the E-AII complex (43, 44). In patients having increased amounts of E-AII complex, HDL2 and HDL3 were found to have larger than normal particle diameters. Large HDL2 rich in apo E have also been described in cases of abetalipoproteinemia (44). Finally, as for some cases of abetalipoproteinemia (40), some of our patients had additional proteins with electrophoretic mobilities intermediate between apo AI and apo AII and unidentified protein bands in the isoelectric focusing gels. The decreased levels of HDL can be interpreted as a consequence of a marked decrease or absence of intestinal triglyceride-rich lipoprotein secretion, whose normal plasma catabolism provides surface material (apo A, apo C, phospholipid) for the maturation of native HDL in the circulation (35). The heterogeneity among the patients with respect to the SDS gel and isoelectric focusing patterns, however, remains unexplained. Nascent HDL have a different apoprotein pattern, depending on their origins: hepatic pro HDL are rich in apo E, in contrast with intestinal pro HDL rich in apo As. Presumably defective secretion of intestinal lipoproteins could result in an HDL apoprotein pattern richer in apo E.

LDL might be expected to exhibit normal levels if the defect in Anderson's disease involves only the intestine. However, this is not the case: total LDL levels are, on the average, ~50% of normal, and this hypobetalipoproteinemia, in fact a reduced level of B100, is a characteristic feature of Anderson's disease.

Figure 8. Isoelectric focusing of HDL apoproteins from normal individuals and Anderson's disease patients. HDL from a normal individual (A); HDL1 from A.B. (B); HDL1 from M.K. (C); HDL1 from A.B. (D); HDL1 from M.K. (E); two patients with Anderson's disease; HDL1 from S.L. (F); a patient with abetalipoproteinemia. The fractions were delipidated and isoelectric focusing performed over a pH 4-6.5 gradient. Some patients, as represented by A.B., have gel patterns similar to normals, while others, represented by M.K., have patterns similar to abetalipoproteinemic individuals.
Further, the LDL composition is markedly altered (in two patients) with an increased amount of triglyceride and phospholipid and decreased amounts of cholesterol. Note, however, that secondary and transient hypobetalipoproteinemia are frequent in other intestinal diseases, associated with severe diarrhea-like celiac disease or sprue. These secondary forms of hypobetalipoproteinemia could result from an increased catabolic rate of LDL or through an enhanced activity of hepatic–receptor-mediated uptake.

Since the primary defect in Anderson's disease seems to be a lack of lipoprotein secretion by the intestine, low levels of LDL and B100 that derive mainly from hepatic VLDL would suggest that B100 synthesis by the liver could be in some way regulated by the influx of B48 as chylomicron remnants. Alternatively, the virtual absence of alimentary fatty acids, a physiological inducer of apo B synthesis and a substrate for VLDL triglyceride synthesis, could result in a decreased VLDL secretion by the liver and subsequently low plasma levels of LDL and B100. Whatever the biochemical mechanism, some relationship seems to exist between chylomicron catabolism and VLDL production by the liver; for instance, in type I hyperlipemia, a primary defect of chyomicron catabolism, low levels of VLDL and LDL are frequently associated with hyperchylomicronemia.

The anomaly of the lipoprotein and apoprotein patterns in Anderson's disease patients involves, besides the apo B-containing lipoproteins, a number of other features: low levels of apo AI, AII, and C, increased amounts of apo E and E–AII complex in HDL, some unidentified apoproteins bands including, perhaps, pro apo AI, abnormal size of HDL particles, etc. Whether this ensemble is secondary to a single genetic error involving intestinal apo B or to a disturbance in chylomicron secretion is, until now, unclear, and deserves further investigation.

Acknowledgments

The authors are indebted to Dr. J. Rey (Hôpital des Enfants Malades, Paris), who initiated the study of Anderson's disease several years ago. Special thanks are due to our technicians, Mrs. N. Verthier for immunoperoxidase studies and Mrs. D. Catala for preparation of polyclonal antibodies. Part of this work was done in Prof. J. Polonovski's laboratory (Centre National de la Recherche Scientifique UA 524, Paris); we would like to thank Dr. S. Goldstein for determination of specificity of some monoclonal antibodies, Mrs. D. Pastier and M. Cagny for excellent technical assistance, and Mr. R. Renbout for preparation of monoclonal antibodies. The authors are specially grateful to Mrs. N. Lachasinki, who collaborated on monoclonal antibodies characterization in the Luzzati laboratory (Centre de Génétique Moléculaire, Centre National de la Recherche Scientifique, Gif/Yvette), to Mrs. E. Audran (Hôpital des Enfants Malades, Paris) for sucrose assays, to Dr. M. Aggerbecke (Institut National de la Santé et de la Recherche Médicale U99, Paris), and to Dr. R. Bertolotti (C.G.M., C.N.R.S., Gif/Yvette), who provided Hep G2 cells.

References


